Small Cell Lung Cancer (SCLC)

>

Latest News

Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.
I-DXd Shows “Impressive” Responses in Extensive-Stage SCLC

September 15th 2025

Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

Numerically higher ORRs were reported in those who received treatment in the second line vs third line, in those with a CTFI of 90 days or more, and those without CNS metastasis.
Lurbinectedin Yields Responses in Various ES-SCLC Subgroups

September 14th 2025

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.
Surufatinib Combo Displays Promising Efficacy in Frontline ES-SCLC

September 12th 2025

In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.
Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

September 11th 2025

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC
Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

September 10th 2025

Latest CME Events & Activities

More News